|
Gene: ATP5F1B |
Gene summary for ATP5F1B |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP5F1B | Gene ID | 506 |
Gene name | ATP synthase F1 subunit beta | |
Gene Alias | ATP5B | |
Cytomap | 12q13.3 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P06576 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
506 | ATP5F1B | GSM4909285 | Human | Breast | IDC | 4.38e-61 | 1.01e+00 | 0.21 |
506 | ATP5F1B | GSM4909286 | Human | Breast | IDC | 1.26e-09 | 1.14e-01 | 0.1081 |
506 | ATP5F1B | GSM4909289 | Human | Breast | IDC | 3.99e-03 | 5.60e-01 | 0.1064 |
506 | ATP5F1B | GSM4909291 | Human | Breast | IDC | 4.61e-07 | 4.69e-01 | 0.1753 |
506 | ATP5F1B | GSM4909293 | Human | Breast | IDC | 1.73e-15 | 3.13e-01 | 0.1581 |
506 | ATP5F1B | GSM4909294 | Human | Breast | IDC | 3.73e-04 | 3.03e-01 | 0.2022 |
506 | ATP5F1B | GSM4909297 | Human | Breast | IDC | 1.32e-03 | 2.85e-02 | 0.1517 |
506 | ATP5F1B | GSM4909298 | Human | Breast | IDC | 1.60e-04 | 7.18e-02 | 0.1551 |
506 | ATP5F1B | GSM4909304 | Human | Breast | IDC | 1.99e-11 | 4.36e-01 | 0.1636 |
506 | ATP5F1B | GSM4909305 | Human | Breast | IDC | 1.29e-10 | 4.21e-01 | 0.0436 |
506 | ATP5F1B | GSM4909306 | Human | Breast | IDC | 1.08e-03 | 2.97e-01 | 0.1564 |
506 | ATP5F1B | GSM4909308 | Human | Breast | IDC | 1.51e-07 | 3.10e-01 | 0.158 |
506 | ATP5F1B | GSM4909311 | Human | Breast | IDC | 6.99e-17 | -1.12e-01 | 0.1534 |
506 | ATP5F1B | GSM4909312 | Human | Breast | IDC | 5.24e-04 | 2.10e-01 | 0.1552 |
506 | ATP5F1B | GSM4909317 | Human | Breast | IDC | 1.98e-11 | 4.37e-01 | 0.1355 |
506 | ATP5F1B | GSM4909318 | Human | Breast | IDC | 7.79e-03 | 5.18e-01 | 0.2031 |
506 | ATP5F1B | GSM4909319 | Human | Breast | IDC | 3.68e-25 | -9.04e-02 | 0.1563 |
506 | ATP5F1B | GSM4909321 | Human | Breast | IDC | 1.98e-27 | 6.42e-01 | 0.1559 |
506 | ATP5F1B | brca1 | Human | Breast | Precancer | 1.63e-27 | -4.97e-01 | -0.0338 |
506 | ATP5F1B | brca2 | Human | Breast | Precancer | 7.84e-25 | -4.97e-01 | -0.024 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00106328 | Lung | IAC | regulation of epithelial cell migration | 55/2061 | 292/18723 | 4.68e-05 | 1.08e-03 | 55 |
GO:00091417 | Lung | IAC | nucleoside triphosphate metabolic process | 27/2061 | 112/18723 | 6.35e-05 | 1.37e-03 | 27 |
GO:00016677 | Lung | IAC | ameboidal-type cell migration | 80/2061 | 475/18723 | 6.90e-05 | 1.47e-03 | 80 |
GO:00427765 | Lung | IAC | mitochondrial ATP synthesis coupled proton transport | 9/2061 | 19/18723 | 7.68e-05 | 1.59e-03 | 9 |
GO:00106347 | Lung | IAC | positive regulation of epithelial cell migration | 36/2061 | 176/18723 | 1.73e-04 | 3.07e-03 | 36 |
GO:00460348 | Lung | IAC | ATP metabolic process | 49/2061 | 277/18723 | 5.44e-04 | 7.59e-03 | 49 |
GO:00091508 | Lung | IAC | purine ribonucleotide metabolic process | 61/2061 | 368/18723 | 7.24e-04 | 9.60e-03 | 61 |
GO:00091527 | Lung | IAC | purine ribonucleotide biosynthetic process | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
GO:00725218 | Lung | IAC | purine-containing compound metabolic process | 67/2061 | 416/18723 | 9.03e-04 | 1.11e-02 | 67 |
GO:00092597 | Lung | IAC | ribonucleotide metabolic process | 62/2061 | 385/18723 | 1.38e-03 | 1.53e-02 | 62 |
GO:00061638 | Lung | IAC | purine nucleotide metabolic process | 63/2061 | 396/18723 | 1.72e-03 | 1.78e-02 | 63 |
GO:00092606 | Lung | IAC | ribonucleotide biosynthetic process | 33/2061 | 182/18723 | 2.71e-03 | 2.48e-02 | 33 |
GO:00196937 | Lung | IAC | ribose phosphate metabolic process | 62/2061 | 396/18723 | 2.72e-03 | 2.49e-02 | 62 |
GO:00061646 | Lung | IAC | purine nucleotide biosynthetic process | 34/2061 | 191/18723 | 3.21e-03 | 2.78e-02 | 34 |
GO:19905426 | Lung | IAC | mitochondrial transmembrane transport | 21/2061 | 102/18723 | 3.34e-03 | 2.86e-02 | 21 |
GO:00725226 | Lung | IAC | purine-containing compound biosynthetic process | 35/2061 | 200/18723 | 3.75e-03 | 3.14e-02 | 35 |
GO:0010594 | Lung | IAC | regulation of endothelial cell migration | 39/2061 | 232/18723 | 4.73e-03 | 3.68e-02 | 39 |
GO:00463906 | Lung | IAC | ribose phosphate biosynthetic process | 33/2061 | 190/18723 | 5.39e-03 | 4.04e-02 | 33 |
GO:00435425 | Lung | IAC | endothelial cell migration | 45/2061 | 279/18723 | 5.62e-03 | 4.14e-02 | 45 |
GO:000914513 | Lung | AIS | purine nucleoside triphosphate biosynthetic process | 21/1849 | 69/18723 | 1.74e-06 | 1.05e-04 | 21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |